Public Viewing of the MedPod by Daya Medicals in Miami features a game-changing patient-centered medication dispensing and data coordinating "cloud" based hub
On December 9 Daya Medicals, Inc. will present its the new dynamic product, the MedPod, to a select group of industry specialists and health care professionals. This will be the first public viewing and demonstration of the product.
- Miami, FL (1888PressRelease) December 04, 2010 - On December 9 at 11am at the Four Seasons Hotel located at 1435 Brickell Avenue in Miami, Daya Medicals, Inc. will present its game-changing patient-centered medication dispensing and data coordinating "cloud" based hub (newest product), the MedPod, to a select group of industry specialists and health care professionals. This will be the first public viewing and demonstration of the product.
The MedPod unit designed by Daya Medicals, Inc. fits in the palm of a hand, is mobile, and is simple to use. All units are pre stocked with prescribed patient-customized drug dosages (prescribed medication) and patient reminder alerts, with light and sound, before being shipped to the patient's door. The unit does require any wifi connection as it uses a cellular technology for communication. Hi-tech tracking allows the physician and any HIPAA approved need-to-know individual in the patient's ecosystem (and/or caregiver) to connect with the patient on a real time basis. Patients maintain compliance with medications and dosing while remaining in control of their home health care.
The MedPod is designed to cut health care costs and risks while increasing patient responsibility, compliance, communication, benefits of home healthcare, control, and peace of mind. The MedPod's inherent telehealth capabilities empower management of fraud and lowers costs. Due to its effective and efficient variety of applications and benefits, initial testing of Daya Medicals, Inc.'s MedPod has already received rave reviews and prescribers from well respected health care providers, government officials, economists, unions, insurance companies, human resources specialists, doctors, hospitals, among others.
Daya Medicals, Inc. plans to manufacture the medication cartridges at their new facility, the life sciences and technology park on campus at the University of Miami, located at 1951 NW 7th Avenue in Miami, initially creating close to 60 jobs in the (initial) introductory phase. Chief Executive and Medical Officer Dr. Kanti Daya says, "The MedPod is unique in that it addresses today's concerns for cost and quality control with health care reform as well as the growing and future needs of general health care. With the expanding growth of the market, it's harder to address both patient and health care provider needs. A unit like MedPod allows patients to help themselves and creates a win-win for all parties, building stronger and more synergistic relationships." Daya adds that additional benefits include insurance incentives, lower drug confusion and abuse, and increased lines of communication between caregiver and patient, eliminating errors, fraud, and waste.
About Daya Medicals, Inc.
Daya Medicals, Inc. is a Pharmaceutical Company with the Prime Directive of Sanitas Pro Omnibus - Health for all. The company empowers and vigorously partners with patients to address diseases and mitigate debility by ameliorating the experiences of aging. These objectives are achieved by minimizing the invasiveness of treatments and enhancing compliance, by expanding access to and integration of data and information on a patient customized basis, by utilizing patient customized clinical information to drive care delivery and minimize errors, and by recognizing and reducing the role of cost to customized patient outcomes. DayaMed has developed next generation technology to achieve these objectives.
The company is additionally fortified with three proprietary products, CarvasinTM - Cardiovascular and Cerebrovascular pathology therapeutic regimen, (Heart Disease Protocol Medication), DST - a Syphilis Screening Test utilized by the US DoD, and The D-Mantoux Tuberculosis Test with two FDA approvals and a third eminently pending Phase One Trials. The portfolio of products includes cardiovascular products, Infectious Disease products, over two hundred generics, laboratory equipment and Diagnostic products.
RSVP is required by emailing RSVP ( @ ) dayamed dot com or by calling Dana Klein at 954-923-4343.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam